Table 2 Meta-analysis results for possible new psoriasis loci

From: Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients

Marker ID Chr Position (hg19)a Alleles (risk/nonrisk) Nearby gene Phenotype comparison Direction (PCKGEI)b Control AFc Case AFc Meta ORd Meta pd
rs9591325 13 50811220 T/C DLEU1 PsV-ctl ++++++ 0.921 0.934 1.25 7 × 10−9
rs7612823 3 101613923 T/C NFKBIZ PsA-ctl ++++++ 0.806 0.836 1.25 3 × 10−8
rs848 5 131996500 C/A IL13 PsA-ctl ++++++ 0.787 0.827 1.27 1 × 10−9
rs588177 11 64024056 C/A PRDX5 PsA-ctl ++−+++ 0.301 0.339 1.20 1 × 10−8
rs1177202 2 61074576 C/G REL PsC-ctl ++++++ 0.566 0.606 1.18 2 × 10−8
rs2111485 2 163110536 G/A IFIH1 PsC-ctl +++++ 0.605 0.641 1.18 4 × 10−8
rs14990525 16 31006289 TGGTGCTA/- FBXL19 PsC-ctl +++++ 0.362 0.402 1.20 9 × 10−10
rs34536443 19 10463118 G/C TYK2 PsC-ctl ?++++ 0.955 0.978 2.08 2 × 10−13
rs34685920 20 48572650 A/− RNF114 PsC-ctl +++++ 0.568 0.608 1.20 1 × 10−10
  1. Chr chromosome, AF allele frequency, OR odds ratio, p p value
  2. aFor insertions or deletions of the reference sequence, position of first base before the insertion point or of first base of the deleted sequence is shown, respectively
  3. bFor six studies of discovery meta-analysis (P = PsA GWAS, C = CASP GWAS, K = Kiel GWAS, G = Genizon GWAS, E = Exomechip, I = PAGE Immunochip) indicates whether OR of risk allele is ≥1 (+), <1 (−), or undetermined due to low imputation quality (?). PsA GWAS directions are only included for PsV-ctl and PsA-ctl, since the PsA GWAS cohort does not contain any patients with PsC subphenotype
  4. cAFs are represented according to the risk allele
  5. dOR and p value for fixed effects meta-analysis with inverse variance weighting